Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Ryan Fukushima sold 10,247 shares of the company's stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $63.02, for a total value of $645,765.94. Following the transaction, the chief executive officer directly owned 652,216 shares in the company, valued at approximately $41,102,652.32. This trade represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Ryan Fukushima also recently made the following trade(s):
- On Monday, November 2nd, Ryan Fukushima sold 80 shares of Tempus AI stock. The shares were sold at an average price of $74.29, for a total value of $5,943.20.
- On Wednesday, September 16th, Ryan Fukushima sold 700 shares of Tempus AI stock. The shares were sold at an average price of $70.00, for a total value of $49,000.00.
- On Friday, August 21st, Ryan Fukushima sold 14,286 shares of Tempus AI stock. The shares were sold at an average price of $70.00, for a total value of $1,000,020.00.
Tempus AI Stock Down 6.3%
Shares of NASDAQ:TEM traded down $4.01 during trading on Thursday, reaching $59.61. 5,290,938 shares of the stock were exchanged, compared to its average volume of 6,229,094. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $89.09. The stock has a fifty day moving average of $72.87 and a two-hundred day moving average of $57.56. The company has a debt-to-equity ratio of 2.70, a current ratio of 2.61 and a quick ratio of 2.48. The firm has a market cap of $10.87 billion, a price-to-earnings ratio of -56.24 and a beta of 3.61.
Tempus AI (NASDAQ:TEM - Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.16. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. The business had revenue of $411.54 million during the quarter, compared to the consensus estimate of $409.39 million. During the same quarter last year, the firm posted ($0.46) EPS. Tempus AI's revenue was up 23.1% compared to the same quarter last year. Research analysts anticipate that Tempus AI, Inc. will post -1.20 earnings per share for the current fiscal year.
Analyst Ratings Changes
TEM has been the subject of a number of recent research reports. Rothschild & Co Redburn assumed coverage on Tempus AI in a report on Tuesday, September 8th. They set a "neutral" rating and a $67.00 price objective for the company. Piper Sandler upgraded shares of Tempus AI from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $56.00 to $76.00 in a research note on Tuesday, September 1st. Roth Capital started coverage on Tempus AI in a research note on Tuesday, September 8th. They issued a "neutral" rating and a $67.00 target price on the stock. BTIG Research upped their target price on Tempus AI from $80.00 to $100.00 and gave the company a "buy" rating in a report on Tuesday, November 3rd. Finally, JPMorgan Chase & Co. upped their target price on Tempus AI from $45.00 to $70.00 and gave the company a "neutral" rating in a report on Wednesday, October 14th. Eleven analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $79.37.
Check Out Our Latest Research Report on TEM
Tempus AI News Roundup
Investors following TEM have been watching these news items:
- Positive Sentiment: Tempus will present 16 abstracts at the 2026 San Antonio Breast Cancer Symposium. The research exposure could showcase its oncology data and precision-medicine capabilities, though the headline does not disclose results or commercial impact. Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $85 price target, indicating substantial potential upside from the cited $59.61 reference price. This is analyst opinion, not a guarantee of performance. HC Wainwright rating information
- Neutral Sentiment: Comparisons with Natera and Grail emphasize Tempus’s AI-enabled data ecosystem, while noting Natera’s growth and positive free cash flow and Grail’s Galleri cancer test trials. These articles provide competitive context rather than a new company-specific catalyst. Natera vs. Tempus AI Grail vs. Tempus AI
Hedge Funds Weigh In On Tempus AI
Institutional investors have recently added to or reduced their stakes in the stock. Eagle Health Investments LP bought a new stake in Tempus AI in the first quarter worth about $11,588,000. Aristotle Atlantic Partners LLC purchased a new stake in Tempus AI in the first quarter worth $6,179,000. Headlands Technologies LLC purchased a new position in shares of Tempus AI during the 2nd quarter valued at $2,689,000. Odyssean LLC bought a new stake in Tempus AI in the 2nd quarter valued at about $897,000. Finally, Fagan Associates Inc. bought a new position in Tempus AI during the third quarter worth about $5,265,000. Institutional investors own 24.22% of the company's stock.
Tempus AI Company Profile
(
Get Free Report)
Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.